Get The App!
Loading the player...
After PV Progression, Which Patients Should Receive Second-Line Ruxolitinib vs IFN?
Share by Email
Send to social websites
Report this video as inappropriate
You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email.
Select your reason
Violent or Repulsive Content
Hateful or Abusive Content
Harmful Dangerous Acts
Dr. Srdan Verstovsek, MD Anderson Cancer Center, answers the following question: After PV progression, which patients should receive second-line ruxolitinib vs IFN?
Do You Attempt to Correct Cytopenias Before Giving Ruxolitinib?
Are MF Patients with RBC Transfusion-Dependent Anemia Considered Candidates for Ruxolitinib Therapy?
Do MF Patients with Low Platelets Have a Different Disease Course/Burden Relative to Those with Norm...
For an HU-Refractory PV Patient on Ruxolitinib, How Would Your Treat after He/She Progresses to Post...
Suggestions for a PMF Patient on Ruxolitinib Who Has Refractory Anemia, but Only Modest Spleen/ Symp...
What Steps Do You Take for Differential Assessment/Treatment of Debilitating Fatigue in Patients wit...
Does Development of HU-Refractory PV Increase a Patient’s Risk for Thrombosis/Cardiovascular Events?...
Would Pregnancy Change the Management of Young Woman with Low-Risk PV? Do You Alter Antithrombotic T...
Copyright 2020 by NSCI Group, Inc.
On The Go
About MedEd On The Go